Wanbury Limited Q2 FY27 Revenue Rises 14.3% to ₹182.91 Crore
Key highlights
- Wanbury's Q2 FY27 standalone revenue rose 14.3% year on year to ₹182.91 crore.
- Standalone profit after tax was ₹11.88 crore in Q2 FY27, down 21.7% year on year but up 266.4% sequentially.
- Gross margin improved to 54.2% in Q2 FY27 from 52.5% in Q1 FY27.
- Wanbury generated ₹37.5 crore of operating cash in H1 FY27 versus a ₹5.7 crore outflow in H1 FY26.
powered by IRIS

Wanbury Limited reported Q2 FY27 standalone revenue of ₹182.91 crore, up 14.3% year on year. The July-September 2026 quarter showed a recovery in revenue after disruptions linked to the West Asia crisis in the preceding quarter, while standalone profit after tax was ₹11.88 crore, down from ₹15.18 crore a year earlier.
Know Wanbury inside out
Results, valuation, peers and who's buying, in one view.
What did Wanbury report for Q2 FY27?
Wanbury reported standalone revenue from operations of ₹182.91 crore for the quarter ended 30 September 2026, compared with ₹160.06 crore in Q2 FY26 and ₹165.6 crore in Q1 FY27. This represented year-on-year growth of 14.3% and sequential growth of 10.5%, according to the company's results statement and press release.
Standalone net profit was ₹11.88 crore, compared with ₹15.18 crore in the corresponding quarter of the previous year. However, profit increased 266.4% sequentially from ₹3.2 crore in Q1 FY27. The company reported standalone operating profit of ₹26.09 crore, marginally higher than ₹25.78 crore in Q2 FY26, while operating margin was 12.0%.
The board approved the unaudited standalone results for the second quarter and first half of FY27, and the company filed the results and review report with BSE and NSE. Wanbury declared the results on 4 November 2026, while its results statement was published on 5 November 2026.
Why did Wanbury's revenue and margins improve sequentially?
Wanbury's sequential revenue growth followed a quarter affected by West Asia crisis-induced disruptions. The company said Q2 revenue reflected recovery from those disruptions, taking revenue from operations to ₹182.9 crore from ₹165.6 crore in Q1 FY27.
The press release reported gross profit of ₹99.1 crore and a sequential improvement in gross margin to 54.2%, from 52.5% in the first quarter. Wanbury attributed the margin movement to passing on a substantial portion of elevated crude-linked raw-material costs to customers. This indicates that customer price revisions partly offset the pressure from input costs during the quarter.
EBITDA, including other income, rose 57.9% sequentially to ₹26.2 crore from ₹16.6 crore in Q1 FY27. The reported standalone operating profit of ₹26.09 crore is broadly consistent with this rounded EBITDA figure. The available disclosures distinguish this improvement from the year-on-year profit comparison, as Q2 FY27 net profit remained below the prior-year quarter's level.
How do the consolidated figures differ from standalone results?
Wanbury reported consolidated revenue from operations of ₹182.91 crore and consolidated profit after tax of ₹8.53 crore for Q2 FY27. Consolidated total income was ₹183.03 crore, profit before tax was ₹12.36 crore, and consolidated earnings per share were ₹2.44.
The company identified this as its first consolidated reporting period following the addition of Wanbury Skin Health, a new subsidiary operating in dermatology and baby care. As a result, comparable consolidated growth rates were not presented. The year-on-year and sequential revenue and profit comparisons in the supplied results details relate to standalone financials.
This distinction is important for investors comparing reported earnings. Standalone profit after tax was ₹11.88 crore and basic earnings per share were ₹3.40, while consolidated profit after tax was ₹8.53 crore and EPS was ₹2.44. The difference reflects the separate reporting scopes rather than a like-for-like comparison between the two profit figures.
Got a follow-up? Ask IRIS
What was Wanbury's first-half financial position?
Wanbury reported standalone revenue of ₹348.5 crore for H1 FY27, an increase of 8% from the prior-year period. Standalone profit after tax for the six months was ₹15.1 crore, compared with ₹28.7 crore in H1 FY26, based on the financial summary provided with the quarterly results.
Operating cash generation improved materially in the first half. Wanbury generated ₹37.5 crore of operating cash in H1 FY27, compared with operating cash outflow of ₹5.7 crore in H1 FY26. This change occurred alongside the recovery in second-quarter revenue and the sequential improvement in profitability.
The first-half figures also show that the stronger Q2 profit did not fully offset the weaker first quarter on a cumulative basis. For market participants, the figures place attention on revenue continuity, raw-material costs and the extent to which price pass-throughs can support margins over subsequent reporting periods.
What do the results mean for investors and operations?
Wanbury's Q2 numbers show higher revenue and improved sequential profitability after the operational disruption cited for Q1 FY27. Revenue growth of 14.3% year on year and the rise in gross margin to 54.2% provide evidence of improved quarterly operating conditions, while the 21.7% decline in standalone profit after tax shows that earnings remained below the prior-year base.
The customer price pass-throughs were a significant factor in the reported margin improvement because crude-linked raw-material costs had risen. The outcome also matters for the pharmaceutical business's operations, where changes in input costs and supply disruptions can affect profitability even when revenue expands.
Wanbury is described in the supplied company information as a micro-cap pharmaceuticals and biotechnology company. No share-price movement linked to the announcement was provided. Therefore, the reported financial data, rather than an inferred market reaction, remains the clearest basis for assessing the quarter.
Conclusion
Wanbury delivered a recovery in Q2 FY27 revenue, with standalone sales reaching ₹182.91 crore and rising 10.5% from Q1 FY27. Higher gross margin, improved EBITDA and positive operating cash generation supported the sequential improvement, but standalone net profit remained lower than in Q2 FY26 and first-half profit was below the prior-year level.
Investors will watch whether revenue recovery continues, whether crude-linked cost pressure remains manageable through customer price pass-throughs, and how Wanbury Skin Health contributes to future consolidated disclosures. The supplied release does not provide comparable historical consolidated data, leaving the new subsidiary's financial contribution an unresolved item for later filings.


